Comparative assessment of the antirestenotic efficacy of two paclitaxel drug-eluting balloons with different coatings in the treatment of in-stent restenosis

Clinical Research in Cardiology

Volumn 105, Issue 5, 2016, Pages 401-411

  Nijhoff, Freek ^a   Stella, Pieter R ^a   Troost, Maartje S ^a   Belkacemi, Anouar ^b   Nathoe, Hendrik M ^a   Voskuil, Michiel ^a   Samim, Mariam ^a   Doevendans, Pieter A ^a   Agostoni, Pierfrancesco ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Drug eluting balloon; In stent restenosis; Paclitaxel; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; BIOCOMPATIBLE COATED MATERIAL; CARDIOVASCULAR AGENT;

AGED; ANGIOGRAPHY; ARTICLE; BALLOON; BALLOON DILATATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRACTIONAL FLOW RESERVE; HUMAN; HYPERLIPIDEMIA; IN-STENT RESTENOSIS; LOADING DRUG DOSE; MALE; NEOINTIMA; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; PROSPECTIVE STUDY; PTCA CATHETER; TREATMENT OUTCOME; ADVERSE EFFECTS; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DEVICES; DIAGNOSTIC IMAGING; HEART CATHETER; MIDDLE AGED; NETHERLANDS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; RISK FACTOR; STENT; TIME FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIAC CATHETERS; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; FEMALE; FRACTIONAL FLOW RESERVE, MYOCARDIAL; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; STENTS; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME;

EID: 84946422804     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-015-0934-0     Document Type: Article

References (30)

1. Tandjung K, Sen H, Lam MK et al (2013) Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial. J Am Coll Cardiol 61:2406–2416
2. Bondesson P, Lagerqvist B, James SK, Olivecrona GK, Venetsanos D, Harnek J (2012) Comparison of two drug-eluting balloons: a report from the SCAAR registry. EuroIntervention 8:444–449
3. Byrne RA, Neumann FJ, Mehilli J et al (2013) Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 381:461–467
4. Kastrati A, Mehilli J, von Beckerath N et al (2005) Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293:165–171
5. Song HG, Park DW, Kim YH et al (2012) Randomized trial of optimal treatment strategies for in-stent restenosis after drug-eluting stent implantation. J Am Coll Cardiol 59:1093–1100
6. Alfonso F, Perez-Vizcayno MJ, Hernandez R et al (2008) Sirolimus-eluting stents versus bare-metal stents in patients with in-stent restenosis: results of a pooled analysis of two randomized studies. Catheter Cardiovasc Interv 72:459–467
7. Stella P, de Jaegere P, Battermann J, Bouma P, Moerland M, Doevendans P (2004) BEta versus Gamma Utrecht Trial-Cypher (BEGUT-CYPHER): is intracoronary brachytherapy still superior to drug-eluting stents? Neth Heart J 12:389–393
8. Scheller B, Hehrlein C, Bocksch W et al (2006) Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 355:2113–2124
9. Xu B, Gao R, Wang J et al (2014) A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. J Am Coll Cardiol Interv 7:204–211
10. Unverdorben M, Vallbracht C, Cremers B et al (2009) Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119:2986–2994
11. Costa MA, Simon DI (2005) Molecular basis of restenosis and drug-eluting stents. Circulation 111:2257–2273
12. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G (2004) Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 110:810–814
13. Joner M, Byrne RA, Lapointe JM et al (2011) Comparative assessment of drug-eluting balloons in an advanced porcine model of coronary restenosis. Thromb Haemost 105:864–872
14. Radke PW, Joner M, Joost A et al (2011) Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. EuroIntervention 7:730–737
15. Buszman PP, Tellez A, Afari ME et al (2013) Tissue uptake, distribution, and healing response after delivery of paclitaxel via second-generation iopromide-based balloon coating: a comparison with the first-generation technology in the iliofemoral porcine model. J Am Coll Cardiol Interv 6:883–890
16. Cortese B, Micheli A, Picchi A et al (2010) Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 96:1291–1296
17. Latib A, Colombo A, Castriota F et al (2012) A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol 60:2473–2480
18. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L (2007) Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356:1009–1019
19. Agostoni P, Belkacemi A, Voskuil M, Nathoe HM, Doevendans PA, Stella PR (2013) Serial morphological and functional assessment of drug-eluting balloon for in-stent restenotic lesions: mechanisms of action evaluated with angiography, optical coherence tomography, and fractional flow reserve. J Am Coll Cardiol Interv 6:569–576
20. Cremers B, Clever Y, Schaffner S, Speck U, Bohm M, Scheller B (2010) Treatment of coronary in-stent restenosis with a novel paclitaxel urea coated balloon. Minerva Cardioangiol 58:583–588
21. Hehrlein C, Richardt G, Wiemer M et al (2011) Description of Pantera Lux paclitaxel-releasing balloon and preliminary quantitative coronary angiography (QCA) results at six months in patients with coronary in-stent restenosis. EuroIntervention 7 Suppl K:K119–K124
22. Stella PR, Belkacemi A, Waksman R et al (2011) The valentines trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment. EuroIntervention 7:705–710
23. Mehran R, Mintz GS, Popma JJ et al (1996) Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis. Am J Cardiol 78:618–622
24. Tada T, Kadota K, Hosogi S et al (2013) Association between tissue characteristics evaluated with optical coherence tomography and mid-term results after paclitaxel-coated balloon dilatation for in-stent restenosis lesions: a comparison with plain old balloon angioplasty. Eur Heart J Cardiovasc Imaging 15:307–315
25. Axel DI, Kunert W, Göggelmann C et al (1997) Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96:636–645
26. Posa A, Nyolczas N, Hemetsberger R et al (2010) Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coronary arteries. Catheter Cardiovasc Interv 76:395–403
27. Speck U, Cremers B, Kelsch B et al (2012) Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Interv 5:392–400
28. Briguori C, Virmani R, Kolodgie F et al (2012) From bench to bedside: initial experience with the Primus drug-coated balloon catheter. Minerva Cardioangiol 60:507–515
29. Yazdani SK, Pacheco E, Nakano M et al (2014) Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter Cardiovasc Interv 83:132–140
30. Nam CW, Rha SW, Koo BK et al (2011) Usefulness of coronary pressure measurement for functional evaluation of drug-eluting stent restenosis. Am J Cardiol 107:1783–1786